Corina BOCŞAN, Adriana BUJOR, Nicolae MİRON, Ştefan C VESA, Diana DELEANU, Anca D BUZOİANU

In Vivo Anti-Inflammatory Effect of H1 Antihistamines in Allergic Rhinitis: A Randomized Clinical Trial

Background: Allergic rhinitis is characterized by a chronic inflammation of nasal mucosa and represents a risk factor for asthma occurrence. H1 antihistamines reduce the symptoms of rhinitis, but some compounds may have anti-inflammatory properties.Aims: We evaluated the plasma level of some cytokines in patients with persistent allergic rhinitis (PAR) and their evolution after a 4-week treatment with H1 anti-histamines, as well as the risk of asthma after 1.5 years.Study Design: Randomized clinical trial.Methods: Eighty-five patients with PAR and 30 healthy volunteers were included in the study. The patients with PAR were randomly divided into 2 groups: 41 patients treated with 5 mg/day desloratadine and 44 patients un-der 5 mg/day levocetirizine for 4 weeks. The clinical and biological evaluations were performed before and after treatment and included rhinitis symptoms and to-tal symptoms score, type of sensitization, and plasmatic levels of total IgE, IL-1?, IL-6, IL-8 and TNF-?.Results: IL-8 and TNF-? were significantly increased in patients with PAR compared to healthy volunteers (5.85 vs 3.12, p

PDF

___

Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, To- gias A, et al; World Health Organization; GA(2)LEN; AllerGen. Allergic rhinitis and its impact on asthma. Allergy 2008;63(Sup- pl 86):8-160.
Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J 2004;24:758-64.
Leynaert B, Neukirch C, Kony S, Guénégou A, Bousquet J, Aubier M, et al. Association between asthma and rhinitis ac- cording to atopic sensitization in a population-based study. J Allergy Clin Immunol 2004;113:86-93.
Min YG. The pathophysiology, diagnosis and treatment of al- lergic rhinitis. Allergy Asthma Immunol Res 2010;2:65-76.
Okayama Y, Kawakami T. Development, migration, and sur- vival of mast cells. Immunol Res 2006;34:97-115.
Prussin C, Metcalfe DD. IgE, mast cells, basophils, and eo- sinophils. J Allergy Clin Immunol 2003;111(Suppl 2):S486-94.
Amin K. The role of mast cells in allergic inflammation. Respir Med 2012;106:9-14.
Bradding P, Roberts JA, Britten KM, Montefort S, Djukanovic R, Mueller R, et al. Interleukin-4, -5, and -6 and tumor necrosis factor-alpha in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines. Am J Respir Cell Mol Biol 1994;10:471-80.
Bradding P. The role of the mast cell in asthma: a reassessment. Curr Opin Allergy Clin Immunol 2003;3:45-50.
Lee NA, Gelfand EW, Lee JJ. Pulmonary T cells and eosino- phils: conspirators or independent triggers of allergic respira- tory pathology? J Allergy Clin Immunol 2001;107:945-57.
Wagenmann M, Schumacher L, Bachert C. The time course of the bilateral release of cytokines and mediators after unilateral nasal allergen challenge. Allergy 2005;60:1132-8.
Ohkubo K, Ikeda M, Pawankar R, Gotoh M, Yagi T, Okuda M. Mechanisms of IL-6, IL-8, and GM-CSF release in nasal secretions of allergic patients after nasal challenge. Rhinology 1998;36:156-61.
Bachert C, van Kempen M, van Cauwenberge P. Regulation of proinflammatory cytokines in seasonal allergic rhinitis. Int Arch Allergy Immunol 1999;118:375-9.
Benson M, Wennergren G, Fransson M, Cardell LO. Altered levels of the soluble IL-1, IL-4 and TNF receptors, as well as the IL-1 receptor antagonist, in intermittent allergic rhinitis. Int Arch Allergy Immunol 2004;134:227-32.
Bachert C, Wagenmann M, Hauser U. Proinflammatory cyto- kines: measurement in nasal secretion and induction of adhesion receptor expression. Int Arch Allergy Immunol 1995;107:106-8.
Bachert C. A review of the efficacy of desloratadine, fexofena- dine, and levocetirizine in the treatment of nasal congestion in patients with allergic rhinitis. Clin Ther 2009;31:921-44.
Ciprandi G, Cirillo I, Vizzaccaro A, Tosca MA. Levocetirizine improves nasal obstruction and modulates cytokines pattern in patients with seasonal allergic rhinitis: a pilot study. Clin Exp Allergy 2004;34:958-64.
Heinzerling L, Mari A, Bergmann KC, Bresciani M, Burbach G, Darsow U, et al. The skin prick test - European standards. Clin Transl Allergy 2013;3:3.
Ciprandi G, Cirillo I, Vizzaccaro A, Civardi E, Barberi S, Al- len M, et al. Desloratadine and Levocetirizine improve nasal symptoms, airflow, and allergic inflammation in patients with perennial allergic rhinitis: a pilot study. Int Immunopharmacol 2005;5:1800-8.
Gosset P, Tillie-Leblond I, Malaquin F, Durieu J, Wallaert B, Tonnel AB. Interleukin-8 secretion in patients with allergic rhi- nitis after an allergen challenge: interleukin-8 is not the main chemotactic factor present in nasal lavages. Clin Exp Allergy 1997;27:379-88.
Gröger M, Klemens C, Wendt S, Becker S, Canis M, Havel M, et al. Mediators and cytokines in persistent allergic rhinitis and nonallergic rhinitis with eosinophilia syndrome. Int Arch Allergy Immunol 2012;159:171-8.
Maiti R, Rahman J, Jaida J, Allala U, Palani A. Rupatadine and levocetirizine for seasonal allergic rhinitis: a comparative study of efficacy and safety. Arch Otolaryngol Head Neck Surg 2010;136:796-800.
Deruaz C, Leimgruber A, Berney M, Pradervand E, Spertini F. Levocetirizine better protects than desloratadine in a nasal prov- ocation with allergen. J Allergy Clin Immunol 2004;113:669-76.
Leurs R, Church MK, Taglialatela M. H1-antihistamines: in- verse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy 2002;32:489-98.
Gillard M, Christophe B, Wels B, Peck M, Massingham R, Chat- elain P. H1 antagonists: receptor affinity versus selectivity. In- flamm Res 2003;52(Suppl 1):S49-50.
Tworek D, Boche?ska-Marciniak M, Kupczyk M, Górski P, Kuna P. The effect of 4 weeks treatment with desloratadine (5mg daily) on levels of interleukin (IL)-4, IL-10, IL-18 and TGF beta in patients suffering from seasonal allergic rhinitis. Pulm Phar- macol Ther 2007;20:244-9.
Reinartz SM, Overbeek SE, Kleinjan A, van Drunen CM, Braunstahl GJ, Hoogsteden HC, et al. Desloratadine reduces systemic allergic inflammation following nasal provocation in allergic rhinitis and asthma patients. Allergy 2005;60:1301-7.
Valero A, Justicia JL, Anton E, Dordal T, Fernández-Parra B, Lluch M, et al. Epidemiology of allergic rhinitis caused by grass pollen or house-dust mites in Spain. Am J Rhinol Allergy 2011;25:e123-8.
Sala-Cunill A, Bartra J, Dalmau G, Tella R, Botey E, Raga E, et al; Comitè de Allergia. Prevalence of asthma and severity of al- lergic rhinitis comparing 2 perennial allergens: house dust mites and Parietaria judaica pollen. J Investig Allergol Clin Immunol 2013;23:145-51.
Sohn SW, Lee HS, Park HW, Chang YS, Kim YK, Cho SH, et al. Evaluation of cytokine mRNA in induced sputum from patients with allergic rhinitis: relationship to airway hyperresponsive- ness. Allergy 2008;63:268-73.